Pfizer Venture Investments

What Pfizer Venture Investments does

Pfizer Venture Investments is the corporate venture capital arm of Pfizer Inc., established in 2004 to deploy strategic capital into biotechnology companies operating in therapeutic areas of current or future interest to Pfizer. The arm pursues minority equity positions and co-investment alongside specialist life-sciences VCs (e.g., Taiho Ventures, Arkin Bio Capital, Polaris Partners), with recent activity concentrated in oncology modalities including T-cell engagers (Crossbow Therapeutics, $77M Series B, March 2026), DNA damage response inhibitors (Artios, $115M Series D, November 2025), and AI-driven cancer drug discovery (Iambic, $100M, November 2025). Pfizer Venture Investments is operated from Pfizer's New York headquarters at 66 Hudson Boulevard East and functions as one component of Pfizer's broader external innovation strategy.

Pfizer Inc., founded in 1849 and listed on NYSE under ticker PFE, is one of the world's largest biopharmaceutical companies with a multi-modal technology platform spanning small molecules, biologics, antibody-drug conjugates (ADCs), bispecific antibodies, mRNA, and vaccines. As of May 5, 2026, the company maintains a pipeline of 96 candidates across Phase 1 (35), Phase 2 (25), Phase 3 (31), and Registration (5), spanning oncology, inflammation & immunology, vaccines, and internal medicine. The oncology research unit is organized into four pillars — Tumor Cell Biology, Bioconjugates Discovery and Development, Precision Medicine, and Integrative Biology and Biochemistry — supporting a marketed portfolio that includes IBRANCE (palbociclib), PADCEV (enfortumab vedotin), TUKYSA (tucatinib), ELREXFIO (elranatamab), and the vaccine ABRYSVO. The Seagen acquisition brought the ADC platform and PADCEV into the portfolio, with co-development partner Astellas Pharma advancing label expansion into muscle-invasive bladder cancer.

Pfizer generates revenue primarily through pharmaceutical product sales across branded prescription medicines, vaccines, and biologics, supplemented by licensing and royalty arrangements (e.g., the BioNTech COVID-19 vaccine collaboration, the Valneva Lyme disease vaccine partnership). Go-to-market combines enterprise field sales to healthcare providers and institutions via the PfizerPro portal, direct-to-consumer engagement through PfizerForAll, traditional pharmacy distribution, and the patient assistance platform Pfizer RxPathways serving uninsured and underinsured patients. Geographic reach spans 10+ major markets including the US, UK, Germany, France, Japan, China, India, Brazil, Australia, and Canada, with the Accord for a Healthier World program extending access on a not-for-profit basis to 1.2 billion people across 45 lower-income countries. The company employs 10,000+ staff globally and is led by managing directors Dan Littman and Helen Hobbs within the venture investments function.

Name

Pfizer Venture Investments

Legal name

Pfizer Inc.

Website

https://pfizer.com

Company type

Public

Founded year

1849

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Pfizer Venture Investments, established in 2004, is the corporate venture capital arm of Pfizer Inc., deploying minority strategic capital into biotech companies aligned with Pfizer's therapeutic areas, particularly oncology. Recent investments span T-cell engagers, DNA damage response inhibitors, and AI-driven cancer drug discovery, complementing Pfizer's broader pipeline of 96 candidates across multiple modalities.

Ownership category

akta.pro rank

Product category

Corporate Venture Capital

NAICS

All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital
• Biotech investments
• Corporate venture capital
• Strategic equity investments
• Healthcare venture investing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sales of branded prescription medicines, vaccines, and biologics across therapeutic areas including oncology, inflammation & immunology, vaccines, and internal medicine. Products are sold through multiple channels including healthcare providers, pharmacies, and directly to consumers.
2. Licensing and Royalty Revenue: Revenue from licensing proprietary technologies, drug compounds, and intellectual property to other pharmaceutical companies. Also includes royalty arrangements from approved products.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Pfizer Venture Investments is the corporate venture capital arm of Pfizer Inc., founded in 2004. It provides strategic equity capital and venture investment funding to early-stage and growth-stage biotechnology companies whose therapeutic focus areas align with Pfizer's strategic interests, particularly in oncology, vaccines, inflammation and immunology, and internal medicine. The firm participates as an investor in private financing rounds alongside other venture capital and strategic partners, targeting companies developing novel modalities such as antibody-drug conjugates, T-cell engagers, DDR inhibitors, and AI-driven drug discovery platforms.

Product overview

Pfizer is a global biopharmaceutical company with a diversified portfolio spanning four therapeutic areas: Internal Medicine (cardiovascular, metabolic, kidney diseases), Inflammation & Immunology, Vaccines, and Oncology. The company maintains an active product pipeline of 96 candidates as of May 2026, including small molecules, biologics (antibody-drug conjugates, bispecific antibodies), and vaccines. Key marketed products include IBRANCE (palbociclib), PADCEV (enfortumab vedotin), TUKYSA (tucatinib), and ELREXFIO (elranatamab) in oncology; HYMPAVZI (marstacimab) for hemophilia; and ABRYSVO for RSV. The company serves patients through programs like Pfizer RxPathways and PfizerForAll, and healthcare professionals through PfizerPro.

Differentiator

Problem solved

Functional benefit

Products and services

• Pfizer Ventures Strategic Equity Investment Program

Quantifiable outcome

• Pfizer RxPathways has connected millions of uninsured and underinsured patients to medications
• +2 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

16 partnerships are on record, tiered core and minor.

• American Cancer SocietycoreStrategic or Co-development Partner · 1 January 2015Pfizer and American Cancer Society launched three-year initiative 'Change the Odds: Uniting to Improve Cancer Outcomes' addressing cancer disparities and improving health outcomes in medically underrepresented US communities.
• AVON Foundation for WomencoreStrategic or Co-development Partner · 1 January 2015Pfizer established grants program with AVON Foundation supporting people living with metastatic breast cancer. In 2015, Avon and Pfizer each contributed $500,000 in grants awarded to 23 nonprofit organizations.
• Union for International Cancer Control (UICC)coreStrategic or Co-development PartnerPfizer and UICC partnered on first-of-its-kind initiative to address challenges facing metastatic breast cancer patients. $760,000 in grants awarded to 20 organizations from 18 countries under SPARC MBC Challenge program.
• Cancer Support Community / The Leukemia & Lymphoma SocietyminorStrategic or Co-development PartnerCollaboration with Chronic Myeloid Leukemia Patient Experience Registry to identify and understand psychosocial and emotional needs of CML patients.
• ASCO/Conquer Cancer FoundationminorStrategic or Co-development PartnerPfizer supported CancerLinQ initiative, a health IT platform designed to improve quality and value of cancer care through real-world data analysis.
• Susan G. KomenminorStrategic or Co-development PartnerPfizer supported Komen Disparities initiative to reduce difference in breast cancer outcomes between African-American and Caucasian women in the US.
• PharmAccessminorStrategic or Co-development PartnerGlobal Health Fellows partnership supporting PharmAccess in Zanzibar and Tanzania to implement public health insurance programs reaching at-risk populations.
• North Star AllianceminorStrategic or Co-development PartnerGlobal Health Fellows partnership supporting mobile health clinics in Kenya through skills-based volunteering program.
• Health BuildersminorStrategic or Co-development PartnerGlobal Health Fellows partnership supporting health systems strengthening in Rwanda.
• Infectious Diseases Institute (Uganda)minorStrategic or Co-development PartnerGlobal Health Fellows partnership supporting HIV/AIDS care and treatment programs in Uganda.
• Save the ChildrenminorStrategic or Co-development PartnerGlobal Health Fellows virtual partnership supporting child health programs globally.
• IFPW FoundationminorStrategic or Co-development PartnerStrategic Training Executive Program (STEP 2.0) partnership providing supply chain training to healthcare professionals across Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, India, Pakistan, and Southeast Asia.
• BioNTechcoreStrategic or Co-development PartnerCollaboration with BioNTech on COVID-19 vaccine development, contributing to global pandemic response.
• ValnevaminorStrategic or Co-development PartnerCollaboration on Lyme Disease Vaccine Candidate (PF-07307405) development.
• Astellas PharmacoreStrategic or Co-development PartnerCo-development agreement with Astellas for PADCEV (enfortumab vedotin) in muscle-invasive bladder cancer (EV-303, EV-304 trials).
• Seagen (Pfizer acquisition)coreStrategic or Co-development PartnerPfizer acquired Seagen to strengthen oncology portfolio, gaining ADC technology platform and approved medicines including PADCEV.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novartis Venture Fund: Corporate venture capital arm of Novartis investing in early-stage biotech with strategic interest to the parent. Directly comparable as a pharma CVC with therapeutic-area alignment to oncology and emerging modalities.
• Roche Venture Fund: CVC arm of Roche with similar early-stage biotech investing focus and parent-company strategic alignment. Directly comparable in mandate, fund structure, and oncology/biologics concentration.
• Johnson & Johnson Innovation (JJDC): Johnson & Johnson's corporate venture arm investing across therapeutic areas with strategic interest to J&J. Comparable as a diversified pharma CVC with similar hold periods and strategic-exit orientation.
• Merck Global Health Innovation Fund (GHIF): CVC arm of Merck & Co. investing in health-tech and biotech adjacencies. Comparable as a major-pharma CVC with strategic alignment to the parent's therapeutic and digital health priorities.
• Sanofi Ventures: Sanofi's corporate venture fund targeting early-stage biotech and digital health aligned with Sanofi's therapeutic areas. Directly comparable in mandate and minority-stake strategy.
• Eli Lilly (Strategic Investment / Lilly Ventures activity): Eli Lilly participates as a strategic investor in biotech rounds (e.g., as an existing investor in Crossbow alongside Pfizer Ventures). Comparable as a peer pharma CVC making selective minority biotech investments.
• Amgen Ventures: CVC arm of Amgen investing in therapeutics, biomanufacturing, and digital health. Comparable as a biotech-major CVC with strategic-exit mandate.
• AbbVie Ventures: AbbVie's corporate venture fund focusing on early-stage biotech in oncology, immunology, and neuroscience. Comparable as a major-pharma CVC with strategic alignment to a focused therapeutic portfolio.
• Takeda Ventures: Corporate venture arm of Takeda investing in early-stage therapeutics. Comparable as a global pharma CVC with minority-investment strategy in biotech.
• Bayer Leaps (Leaps by Bayer): Bayer's CVC/impact-investing vehicle focused on biotech and health-tech with breakthrough potential. Comparable as a major-pharma CVC with strategic capital deployment mandate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xtwitter.com/Pfizer
• YouTubeyoutube.com/Pfizer
• Facebookfacebook.com/Pfizer
• LinkedInlinkedin.com/company/pfizer-ventures
• Instagraminstagram.com/Pfizerinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments205 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer Venture Investments